BPC-157 is a synthetic fifteen amino acid peptide, not approved as a medicine anywhere, with an unusually large animal literature and a very small human one. A 2025 systematic review of the orthopaedic literature identified 36 studies published between 1993 and 2024, and almost all of them are animal work. The human evidence that exists comes from trials in inflammatory bowel disease run in the early 2000s, not from anything in muscle, tendon or joint research.
That gap is the whole story of this compound. The enthusiasm is real, the petri dish and rodent data are extensive, and the human data is thin in a way that rarely gets stated plainly. What follows separates the three.
In This Guide
- What BPC-157 actually is
- What the animal research shows
- What human data exists
- What it has not been shown to do
- Safety, and the specific concerns regulators name
- Legal and anti-doping status
- FAQ
What BPC-157 actually is
The name stands for body protection compound, and it comes from a fragment of a protein found in human gastric juice. It is a pentadecapeptide, meaning fifteen amino acids, and it is studied as a stable synthetic version rather than being extracted from anything.
| Property | What is known |
|---|---|
| Structure | Synthetic pentadecapeptide, fifteen amino acids, derived from a gastric juice protein fragment |
| Half-life | Under 30 minutes in animal studies. No human pharmacokinetic study has been published, so there is no human figure at all |
| Forms studied | Injectable in most animal work; oral and rectal forms used in the human inflammatory bowel disease trials |
| Approval status | Not approved as a medicine in the United States, the EU or the UK |
| Sport status | Prohibited. Named explicitly in WADA’s S0 category of non-approved substances |
| Regulatory flag | Listed on the FDA page of bulk drug substances for compounding that may present significant safety risks |
The half-life figure deserves its own sentence. Under 30 minutes comes from rodent and dog work, not from people, and it is routinely repeated online as though it were measured in humans. Our peptide half-life chart marks it as animal data for that reason.
What the animal research shows
The animal literature is broad and consistent in direction. Across the models used, BPC-157 has been reported to accelerate healing in tendon, ligament, muscle, bone, gut lining and nerve tissue, and to interact with the nitric oxide system and with growth factor signalling such as VEGF, which is the proposed explanation for the vascular effects often described.
Two things about that body of work are worth holding in mind at the same time. It is more extensive than most compounds in this category, which is why the compound has a reputation at all. And it is animal work: rodent models with induced injuries, small numbers, and outcome measures that are easier to show a difference in than a human clinical endpoint like return to sport.
What human data exists
There is more human data than the phrase “no human trials” suggests, and it is narrower than the internet implies.
- Inflammatory bowel disease. Phase II clinical work was conducted in the early 2000s, with BPC-157 given by injection and rectally. The published reviews describe it as having been tested in clinical phase II, and it is the only substantial human dataset for this compound.
- Everything else. Tendon, muscle, joint and nerve outcomes rest on animal models. Case reports and clinic write-ups exist, and they are not controlled trials, whatever the marketing around them says.
If you want to check the registry yourself rather than take my word for it, search the term on ClinicalTrials.gov. What you will find is the point of this section: for a compound this widely discussed, the registered human trial record is remarkably empty.
What it has not been shown to do
| Claim | State of the evidence |
|---|---|
| Heals tendon and ligament injuries in humans | Not demonstrated. Tendon healing is shown in animal models only |
| Builds muscle or increases strength | No human evidence. Not a growth or anabolic agent, and it is not studied as one in any controlled human work |
| Repairs the gut in humans | The closest thing to human evidence, from the early inflammatory bowel disease work, and it is not the same as evidence for general gut support in healthy people |
| Works systemically after oral use | Unclear. Oral and rectal dosing were used in the bowel trials, and human pharmacokinetics have never been published |
| Is safe because it is a fragment of a human protein | An origin story, not a safety dataset. See the regulatory flag below |
| Has a known human half-life of two hours | Wrong number and wrong species. The published figure is under 30 minutes, in animals |
Safety, and the specific concerns regulators name
There is no human safety database of the kind that comes with an approved medicine: no defined dose range with adverse event rates, no long-term follow-up, no interaction data. What there is, instead, is a regulator’s stated concern.
The FDA lists BPC-157 among the bulk drug substances for use in compounding that may present significant safety risks, and the stated reason is specific rather than general: compounded drugs containing it may pose risk for immunogenicity for certain routes of administration, and may have complexities around peptide-related impurities and characterisation of the active ingredient. In plain terms, the concern is that a foreign peptide given repeatedly can provoke an immune response, and that the purity profile of unapproved supply is not controlled.
There is one more thing worth saying plainly, because it applies to this whole category: what is in the vial is not guaranteed to be the peptide on the label. For a compound with no approved manufacturing standard, the only check available to a buyer is a certificate of analysis matched to the batch.
Legal and anti-doping status
- Not an approved drug. No regulator has approved BPC-157 for human use, which means no approved product, no approved indication, and no approved dose.
- Sport. BPC-157 is named explicitly in the World Anti-Doping Agency’s S0 class of non-approved substances, and it is on the prohibited list. USADA has published separately on the risk this creates for athletes, including the risk of an inadvertent positive test.
- Compounding. The FDA’s peptide categorisation has been moving through 2026, with a group of peptides removed from the Category 2 list in April. Removal from a flag list is not approval, and it does not make a product legal to sell as a supplement. Check the current FDA page before relying on any status you read about.
For the wider picture of how peptides, growth hormone and HCG differ in form, storage and verification, see the guide to peptides, HGH and HCG. Further guides are collected in the peptides section.
FAQ
Is BPC-157 approved for human use?
No. It is not approved as a medicine by the FDA, the EMA or the MHRA. It is sold as a research chemical and discussed as a supplement, which is not the same as being approved for human use.
Have there been human trials of BPC-157?
Yes, but only in one area. Phase II work in inflammatory bowel disease was run in the early 2000s using injected and rectal dosing. Beyond that, tendon, muscle, joint and nerve claims rest on animal studies, and the registered human trial record is otherwise empty.
What is the half-life of BPC-157?
Under 30 minutes, measured in rats and dogs. No human pharmacokinetic study has been published, so the human half-life is unknown. The commonly quoted two hour figure is wrong on both the number and the species.
Does BPC-157 build muscle?
There is no human evidence for that, and it is not studied as an anabolic or growth agent. The literature is about tissue repair in animal models and gut inflammation in humans.
Is BPC-157 banned in sport?
Yes. It is named in the WADA prohibited list under S0, the class for non-approved substances, and USADA has warned athletes specifically about it.
Why does the FDA flag it?
The agency lists it among bulk drug substances for compounding that may present significant safety risks, citing potential immunogenicity for certain routes of administration and difficulties with peptide impurities and characterising the active ingredient.
Can I take it orally?
Oral and rectal dosing were used in the inflammatory bowel disease trials, so the route has been studied in that setting. Human pharmacokinetics have never been published, which means how much reaches circulation after oral use is unknown, and the peptide is vulnerable to digestion.
What should I check if I am looking at a product?
Whether a batch-matched certificate of analysis exists, whether the purity method is stated, and whether the seller makes claims that the published research does not support. Claims that outrun the evidence are the most reliable signal of a bad supplier.
Last reviewed: October 2026 by Julian Hart. This page is educational and is not medical advice, and it is not an endorsement or an instruction for using any substance. BPC-157 is not approved for human use, and anything involving dosing or a health condition belongs with a qualified clinician.
Sources
- McGuire FP, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 36 studies, 1993 to 2024.
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157. 2025.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157, including the phase II clinical work in inflammatory bowel disease. 2012.
- He L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC-157 in rats and dogs. 2022. Elimination half-life under 30 minutes.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, including the stated concerns for BPC-157.
- WADA. The Prohibited List, S0 non-approved substances, which names BPC-157.
- USADA. BPC-157: experimental peptide creates risk for athletes.
- ClinicalTrials.gov search for BPC-157, for the registry record cited in this article.
